What's in BioVersys AG's pipeline?

BioVersys AG has 6 drugs in our index: 0 marketed, 0 filed, 1 in Phase 3, 4 in Phase 2, 1 in Phase 1.

Which companies overlap with BioVersys AG's portfolio?

Top competitors by shared drug class: Achaogen, Inc., Assistance Publique - Hôpitaux de Paris, Bausch Health Americas, Inc., Bosnalijek D.D, Capital Medical University.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/bioversys-ag.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-14 · How we verify

BioVersys AG — Portfolio Competitive Intelligence Brief

BioVersys AG pipeline: 0 marketed, 0 filed, 1 Phase 3, 4 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 4 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Best Available Therapy (BAT)	Best Available Therapy (BAT)	phase 3

Therapeutic area mix

Infectious Disease · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Achaogen, Inc. · 1 shared drug class
Assistance Publique - Hôpitaux de Paris · 1 shared drug class
Bausch Health Americas, Inc. · 1 shared drug class
Bosnalijek D.D · 1 shared drug class
Capital Medical University · 1 shared drug class
Dr. Reddy's Laboratories Limited · 1 shared drug class
Incheon St.Mary's Hospital · 1 shared drug class
Jomaa Pharma GmbH · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for BioVersys AG:

Cite this brief

Drug Landscape (2026). BioVersys AG — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/bioversys-ag. Accessed 2026-05-14.